Mutations in Tepary Bean Lectin Reduce Its Cancer Cell Killing Ability
Author Information
Author(s): Martínez-Alarcón Dania, Castro-Guillén José Luis, Fitches Elaine, Gatehouse John A., Przyborski Stefan, Moreno-Celis Ulisses, Blanco-Labra Alejandro, García-Gasca Teresa
Primary Institution: Centro de Investigación y de Estudios Avanzados Unidad Irapuato, Departamento de Biotecnología y Bioquímica, Irapuato, Mexico
Hypothesis
The arginine residues R103 and R130 in the recombinant Tepary bean lectin (rTBL-1) are crucial for its cytotoxic activity against colon cancer cells.
Conclusion
Substituting arginine residues R103 and R130 with glutamines significantly reduces the cytotoxic activity of the Tepary bean lectin against colon cancer cells.
Supporting Evidence
- Mutations in the lectin reduced its ability to bind to cancer cell glycans.
- R130Q mutant was found to be three times less cytotoxic than the original lectin.
- R103Q mutant showed a 1.5 times reduction in cytotoxicity compared to the original lectin.
- Both mutants maintained their ability to form homo-tetramers.
- Significant differences in cytotoxicity were observed between the original and mutant lectins.
Takeaway
Scientists changed some parts of a bean protein to see how it affects its ability to kill cancer cells, and found that changing two specific parts made it much less effective.
Methodology
The study involved creating two mutants of the recombinant Tepary bean lectin by substituting arginine residues with glutamines, followed by biochemical characterization and cytotoxicity assays on HT-29 colorectal cancer cells.
Limitations
The study primarily focused on two specific mutations and their effects, which may not encompass all potential variations affecting lectin activity.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website